×
About 1,173 results

ALLMedicine™ Atypical Hemolytic Uremic Syndrome Center

Research & Reviews  432 results

Complement Gene Variant Effect on Relapse of Complement-Mediated Thrombotic Microangiop...
https://doi.org/10.1182/bloodadvances.2021006416
Blood Advances; Acosta-Medina AA, Moyer AM et. al.

May 10th, 2022 - Eculizumab is effective for complement-mediated thrombotic microangiopathy (CM-TMA), also known as atypical hemolytic uremic syndrome. Although lifelong therapy had been suggested, discontinuation does not universally lead to relapse. Comprehensiv...

Atypical hemolytic uremic syndrome induced by SARS-CoV2 infection in infants with EXOSC...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072151
Pediatric Nephrology (Berlin, Germany); Van Quekelberghe C, Latta K et. al.

May 7th, 2022 - Atypical hemolytic uremic syndrome (aHUS) is a rare disease characterized by systemic thrombotic microangiopathy mainly in the kidneys and mostly due to genetic disorders leading to uncontrolled activation of the complement system. Severe complica...

Mycoplasma pneumoniae Infection Associated with Anti-Factor H Autoantibodies in Atypica...
https://doi.org/10.1159/000523998
Nephron Valoti E, Piras R et. al.

Apr 12th, 2022 - Hemolytic uremic syndrome (HUS) is a rare disease characterized by hemolytic anemia, thrombocytopenia, and renal impairment mostly triggered by strains of Shiga-like toxin-producing Escherichia coli (STEC-HUS). A rarer form of HUS, defined as atyp...

Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)
https://clinicaltrials.gov/ct2/show/NCT03131219

Apr 12th, 2022 - The purpose of the study is to assess the efficacy of ravulizumab to control disease activity in children and adolescents with aHUS who have not previously used a complement inhibitor (complement inhibitor treatment-naïve), as well as in complemen...

see more →

Guidelines  3 results

Clinical guides for atypical hemolytic uremic syndrome in Japan.
https://doi.org/10.1007/s10157-016-1276-6
Clinical and Experimental Nephrology; Kato H, Nangaku M et. al.

Jul 17th, 2016 - Atypical hemolytic uremic syndrome (aHUS) is a rare disease characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. In 2013, we developed diagnostic criteria to enable early diagnosis and timely ...

An international consensus approach to the management of atypical hemolytic uremic synd...
https://doi.org/10.1007/s00467-015-3076-8
Pediatric Nephrology (Berlin, Germany); Loirat C, Fakhouri F et. al.

Apr 11th, 2015 - Atypical hemolytic uremic syndrome (aHUS) emerged during the last decade as a disease largely of complement dysregulation. This advance facilitated the development of novel, rational treatment options targeting terminal complement activation, e.g....

Guideline for the investigation and initial therapy of diarrhea-negative hemolytic urem...
https://doi.org/10.1007/s00467-008-0964-1
Pediatric Nephrology (Berlin, Germany); Ariceta G, Besbas N et. al.

Sep 19th, 2008 - This guideline for the investigation and initial treatment of atypical hemolytic uremic syndrome (HUS) is intended to offer an approach based on opinion, as evidence is lacking. It builds on the current ability to identify the etiology of specific...

see more →

Drugs  3 results see all →

Clinicaltrials.gov  9 results

Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)
https://clinicaltrials.gov/ct2/show/NCT03131219

Apr 12th, 2022 - The purpose of the study is to assess the efficacy of ravulizumab to control disease activity in children and adolescents with aHUS who have not previously used a complement inhibitor (complement inhibitor treatment-naïve), as well as in complemen...

Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients
https://clinicaltrials.gov/ct2/show/NCT03518203

Dec 14th, 2021 - This clinical trial is a prospective single arm multi-institution study in children and young adults undergoing allogeneic or autologous hematopoietic stem cell transplantation who will receive early therapy with eculizumab to prevent TMA-associat...

Complement Regulation to Undo Systemic Harm in Preeclampsia
https://clinicaltrials.gov/ct2/show/NCT04725812

Sep 16th, 2021 - The purpose of this study is to determine if eculizumab is an effective treatment to prolong pregnancy in women with preeclampsia, compared to a historical control group of women that received standard of care alone. Eligible subjects will be wome...

Complement Prospective Evaluation of Thrombotic Microangiopathy on Endothelium
https://clinicaltrials.gov/ct2/show/NCT04745195

Aug 23rd, 2021 - Thrombotic microangiopathy (TMA) is a severe and life-threatening condition, often affecting the kidneys and brain. It can occur on the background of various clinical conditions. Dysregulation of the alternative pathway of complement may be the et...

see more →

News  22 results

MRD-Guided Therapy Could Inform Treatment-Free Surveillance in Newly Diagnosed Multiple Myeloma
https://www.onclive.com/view/mrd-guided-therapy-could-inform-treatment-free-surveillance-in-newly-diagnosed-multiple-myeloma

Dec 12th, 2021 - Minimal residual disease (MRD), assessed through next-generation sequencing (NGS) was found to inform treatment selection and duration with daratumumab (Darzalex) plus carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (Dara-KRd) f...

Phase 3 Drug Trial for ALS Halted for Lack of Efficacy
https://www.medscape.com/viewarticle/957004

Aug 20th, 2021 - A global phase 3 trial of ravulizumab (Ultomiris) for adults with amyotrophic lateral sclerosis (ALS) is being discontinued following a data review, its manufacturer has announced. The CHAMPION-ALS placebo-controlled trial had enrolled 382 adults ...

Transplant-Associated Thrombotic Microangiopathy: New Insights, Emerging Treatments
https://www.onclive.com/view/transplant-associated-thrombotic-microangiopathy-new-insights-emerging-treatments

Jul 22nd, 2021 - Transplant-associated thrombotic microangiopathy (TA-TMA) is a complication of stem cell transplants that can occur with peripherally mobilized stem cells or bone marrow-derived stem cells. TA-TMA remains a difficult complication to address, with ...

A Retrospective Look at the Management of HSCT-TMA
https://www.onclive.com/view/a-retrospective-look-at-the-management-of-hsct-tma

Apr 2nd, 2021 - Transcript: Sergio A. Giralt, MD: Transplant-associated TMA [thrombotic microangiopathy] is actually a relatively newly identified disorder. It does fall into the thrombotic microangiopathies, which started with thrombocytopenia, thrombotic pu...

Addressing Diagnostic Challenges in HSCT-TMA and Exploring Emerging Biomarkers
https://www.onclive.com/view/addressing-diagnostic-challenges-in-hsct-tma-and-exploring-emerging-biomarkers

Oct 30th, 2020 - Biomarkers predictive of risk in hematopoietic stem cell transplantation (HSCT)–associated thrombotic microangiopathy (TMA) have undergone a recent evolution, with several new markers under exploration and many efforts focused on making current ma...

see more →